Adherium expands international presence and announces new appointments

Company News

Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has announced Mr Thomas Lynch as its new chairman and Dr Doug Wilson as executive medical director.

The company said Mr Lynch’s appointment follows a global search for a high profile director with broad international experience in the healthcare sector in North America and Europe.

Mr Lynch has extensive experience of biotechnology and specialty pharma. He has just stepped down as chair of Icon, one of the world's largest clinical research organisations having served on its board for 22 years.

He is also chair of Evofem Biosciences and Profectus Biosciences, two privately-held US biotechnology companies. Mr Lynch serves as a non-executive director of GW Pharma, a biotechnology company listed on NASDAQ and AIM. In a pro bono capacity, Mr Lynch serves as chair of the Ireland East Hospital Group, the largest hospital group in Ireland. He has also served in a range of roles at Elan Corporation and Amarin Corporation. Throughout his career, Mr Lynch has been involved in the listing of a number of companies on the NASDAQ market and brings significant international capital markets experience to Adherium.

Dr Wilson is stepping down from the board, moving to a part-time executive role as Adherium’s medical director, where he will work closely with the management team to assist in steering the company’s clinical development and strategic path for the next phase of growth. He described his departure at the anniversary of the IPO and the first year as a public company, as timely, as the year has seen the company grow to 50 personnel, and a significantly expanded breadth of market opportunities. 

The company said recently established business hubs in the US and UK are accelerating its access to new business.

The Adherium technology platform is developing with new devices incorporating more sensors to broaden the application beyond drug detection to inhaler technique and other data.

The first Adherium device that uses its technology beyond-the-inhaler has been developed, and a new suite of web services have been released. 

Adherium’s Group CEO, Garth Sutherland, said: “On behalf of the Adherium Board, we offer our sincere thanks to Dr Wilson for the major contribution he has made to Adherium’s growth over the last four years, and we warmly welcome Mr Thomas Lynch to the Adherium Board for our next major phase of growth.”